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Abstract 
Antimicrobial activity of Usnea barbata especially against bacteria involved in pathogenesis
of various skin conditions has been well documented in literature. Nevertheless, there are 
no papers dealing with formulation of its isolates into topical preparations for treatment of
skin infections. In present study, alkyl polyglucoside (APG)-based vehicle was developed as 
carrier of U. barbata CO2-supercritical extract (U-SE) that demonstrated the best anti-
microbial potential in preliminary screening. For comparison, chosen extract in the same 
concentration and using the same procedure was incorporated into a pharmacopoeial
vehicle. Comparative evaluation of physicochemical stability, efficiency and safety proved
APG-based vehicle to possess certain preferential features as carrier of U-SE compared to 
the reference one, composing a topical formulation with potential clinical relevance in 
treatment of skin infections. 
Keywords: alkyl polyglucosides, Usnea barbata supercritical CO2-extract, skin infections,
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Usnea barbata is one of the most studied lichens 
belonging to the genus Usnea, traditionally used in 
Asia, Africa and Europe for pain relief and fever control. 
According to literature data, U. barbata (UB) has alle-
gedly been used by Hippocrates to treat urinary com-
plaints and in folk medicine of South Africa for the 
treatment of wounds [1,2]. In addition to traditionally 
claimed properties of UB as a folk remedy, German 
Commission E approved its usage as an antimicrobial 
agent intended for the treatment of mild inflammation 
of the oral and pharyngeal mucosa in the form of loz-
enges [3].  
Antimicrobial activity of UB has been fairly docum-
ented in several scientific studies [2,4,5]. Comparative 
testing of acetone, methanol and water extract of UB 
against 10 bacterial and 5 fungal strains using dilution 
method on solid agar medium revealed the best anti-
microbial activity against Gram positive bacteria, with 
acetone extract being the most active among the 
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investigated extracts [2]. Furthermore, an investigation 
of acetone extracts of several Usnea species including 
UB using agar disc diffusion method demonstrated 
antimicrobial activity to be proportional to usnic acid 
(UA) content in the investigative extracts [4]. Similar 
results were reported in a recent study screening nine 
plant extracts and isolated compounds for antimicro-
bial activity against bacteria and yeasts with derma-
tological relevance. Namely, supercritical CO2-extract of 
UB in a form of a suspension with 4 mass% of UA and 
pure UA were the most active compounds, especially 
effective against anaerobic and Gram-positive bacteria 
as well as dimorphic yeast Malassezia furfur. Moreover, 
it was suggested that antimicrobial activity of the ext-
ract was mainly mediated by UA [5]. To the best of our 
knowledge, there are not papers regarding formulation 
of UB extracts into pharmaceutical preparations for the 
treatment of skin disorders. 
Bearing in mind the above statements, the object-
ive of our study was to develop and evaluate a phar-
maceutical topical formulation with UB extract as an 
active ingredient for the treatment of skin infections. 
The current investigation consisted of two parts. The 
aim of the first part was screening of several UB ext-
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racts prepared using different protocols and/or sol-
vents, in terms of their UA content and antimicrobial 
activity, as well as correlation thereof. The extract with 
the best antimicrobial potential against bacteria that 
commonly cause skin infections was further chosen for 
the second part of the study. In this part, our objective 
was to formulate selected extract into oil-in-water 
(O/W) emulsion and evaluate its physicochemical sta-
bility, as well as efficiency and safety features. We 
aimed at developing a vehicle with emollient properties 
as carrier for UB extract, being prospective topical anti-
microbial, considering the potential of emollients 
(moisturizers) to restore skin barrier function accom-
panying skin infections, while soothing its concomitant 
symptoms [6]. In this regard, for stabilization of inves-
tigated emulsion we used alkyl polyglucoside (APG) 
emulsifiers, prepared from natural renewable raw mat-
erials, which have been gaining increasing attention in 
recent years due to their favorable ecological, toxicol-
ogical and dermatological properties [7,8]. For com-
parison with the developed emulsion, chosen UB ext-
ract in the same concentration and using the same pre-
paration procedure was incorporated into widely used 
conventional (pharmacopoeial) vehicle, used as a refer-
ence. 
EXPERIMENTAL 
Preparation of UB extracts 
Lichen UB was collected in the Former Yugoslav 
Republic of Macedonia (GPS N41 53.5764 E21 33.6348) 
on 15th of October, 2009. The lichen was identified at 
the Faculty of Biology, University of Belgrade (voucher 
of specimen No. 16390/10.04.2010.). Ethanol 96.3 
vol.% was purchased from Vranje, Serbia and ether 
from Carlo Erba Reagents, France.  
Investigated samples were following UB extracts: 
supercritical CO2 extract (U-SE), Soxhlet extracts (ether 
fraction (U-SOX-E) and ethanol fraction (U-SOX-EtOH)) 
and macerate (U-MAC). 
U-SE was purchased from Flavex, Germany. Accord-
ing to manufacturer’s claims U-SE was obtained by the 
method of supercritical CO2 extraction, and then puri-
fied in a second step to practical pure UA (drug:extract 
ratio (DER) 62–100:5). Samples U-SOX-E and U-SOX- 
-EtOH were obtained by repeated continuous extract-
ion using Soxhlet apparatus. 75.0 g of dried UB, grinded 
to the size of 180 mesh, was measured in each of five 
thimbles used, covered with appropriate amount of 
ether and extracted until ether discoloration. There-
after, the same procedure as for U-SOX-E was utilized 
with ethanol 96.3 vol.% using thimbles with plant mat-
erial already extracted with ether, in order to obtain 
U-SOX-EtOH. For the preparation of U-MAC, 93.91 g of 
dried UB grinded to the size of 180 mesh was covered 
with 600 mL of ethanol 70 vol.%, macerated for 24 h 
and then filtered. After all extractions, liquids were 
evaporated using rotary evaporator Buchi R 114, USA, 
yielding 2.04, 6.71 and 5.41 % residues for U-SOX-E, 
U-SOX-EtOH and U-MAC respectively, expressed as dry 
matter. 
UA assay in UB extracts 
UA was assayed using Hewlett Packard HPLC model 
1200; column Zorbax Eclipse XDB-C18 600 Bar (4.6 
mm×100 mm, 1.8 µm). The mobile phase A consisted 
of 99% H2O and 1% H3PO4, while B was acetonitrile. 
Flow rate was 0.1 mL/min, and elution was as follows: 
11–55% B, 0–5 min; 55–80% B, 5–10 min; 80% B, 10–12 
min; 80–100% B, 12–20 min; 100% B, 20–35 min, 100– 
–11% B, 35–40 min, 11% B, 40–55 min. Investigated 
samples (in triplicate) were prepared in a following pro-
cedure: 5.0, 7.1, 18.9 and 61.3 mg of U-SE, U-SOX-E, 
U-SOX-EtOH and U-MAC, respectively were dissolved in 
50 mL methanol (analytical grade, purchased from 
Merck, Germany) then filtered through 0.45 μm PTFE 
syringe filters into glass HPLC vials and analyzed as 
described above. Commercially available UA, used as a 
reference standard was bought from Santa Cruz Bio-
technology, USA, with the purity declared as > 98%. 
Preparation of O/W creams 
Test cream sample (labeled ML) was stabilized with 
mixed non-ionic APG emulsifier Montanov® L (INCI/C12–14 
glucoside and C12–14 alcohol). A preliminary formulation 
study, conducted in accordance with manufacturer’s 
recommendations, showed that the emulsifier concen-
tration used (8 mass%) allowed the formation of 
creams with satisfactory organoleptic characteristics. 
For co-stabilization, a novel co-emulsifier Montanov® S 
(INCI/ cocoglucoside and coconut alcohol) was used in 
the concentration of 2 mass%, in accordance to manu-
facturer’s recommendations. The emulsifiers were 
kindly provided by Seppic, France. The oil phase com-
prised caprylic-capric triglycerides (Sabo, Italy) and 
cetostearyl alcohol (Sabo, Italy), while the water phase 
was the mixture of 85% glycerol and water preserved 
using potassium sorbate. 
Non-ionic hydrophilic cream (DAB 2011), used as a 
reference vehicle of pharmacopoeial quality (labeled 
P), was stabilized with mixed non-ionic emulsifier com-
prising Polysorbate 60 (Merck, Germany) and ceto-
stearyl alcohol (Sabo, Italy). The oil phase contained 
white soft paraffin (Sigma Aldrich, Germany), while the 
water phase consisted of 85% glycerol and water pre-
served with potassium sorbate [9]. Detailed compo-
sition of investigated samples is given in Table 1. 
Selection of the extract concentration was per-
formed in the context of UA content, as a carrier of the 
stated biological activity of the extract. In accordance 
to our previous investigations (data not shown), chosen 
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concentration of the extract corresponded to 2 mass% 
of UA. In addition, selected extract concentration was 
supported by the literature data [10]. Upon the addi-
tion of extract, active samples were labeled ML-U and 
P-U. Double distilled water was used for the prepar-
ation of all samples. Compounds used were of pharma-
copoeial quality (Ph. Eur.), whenever possible. 
Table 1. Composition (mass%) of investigated vehicles (alkyl 
polyglucoside-stabilized vehicle (ML) and pharmacopoeial 
vehicle (P)) 
Component ML P 
Caprylic-capric triglycerides 18.5 – 
Cetearyl alcohol 1.5 10.0 
C12-14 glucoside and C12-14 alcohol 8.0 – 
Cocoglucoside and coconut alcohol 2.0 – 
Polysorbate 60 – 5.0 
White soft paraffin – 25.0 
Glycerol, 85% 5.0 10.0 
Potassium sorbate 0.5 0.5 
Water, double distilled  64.5 49.5 
APG-stabilized vehicle was prepared by heating the 
emulsifiers and oil phase at 70-75 °C and then adding 
them to the preserved water phase at the same tem-
perature by stirring (stirrer RW16 basic, IKA, Germany) 
at constant temperature for 3 min at 800 rpm and then 
3 min at 500 rpm. Cooling was started at 500 rpm for 1 
min and then at 300 rpm to the room temperature. 
Referent non-ionic hydrophilic cream was prepared 
according to DAB 2011 [9]. Briefly, white soft parrafin 
together with Polisorbate 60 and cetostearyl alcohol 
(oil phase) were heated to 70 °C. Components of the 
aqueous phase were heated to the same temperature, 
and then added to the oil phase and stirred until cooled 
to the room temperature. Active samples (ML-U and 
P-U) were prepared by suspending UB extract into 
appropriate vehicles. More precisely, the extract was 
rubbed with glycerol, using mortar and pestle, followed 
by addition of portions of vehicle. Prepared samples 
were allowed 7 days equilibration before being submit-
ted to selected characterization techniques. 
Rheological measurements 
The rheological characterization was conducted in 
order to evaluate preliminary physical stability of inves-
tigated samples, especially in terms of the influence of 
UB extract addition to both types of investigated bases 
in a predetermined period of time. Additionally, flow 
properties were assessed as parameters known to 
exhibit influence on sensory properties of semisolids, 
crucial for patient acceptability [11]. 
Continual measurements were performed after 7, 
30 and 90 days of storage at room temperature 
(Rheometer Rheolab MC 120, Paar Physica, Germany). 
All measurements were carried out using cone/ plate 
measuring system (diameter 50 mm, angle 1°), with 
0.05 mm sample thickness, at 20±0.1 °C (in triplicate). 
Controlled shear rate procedure was applied (shear 
rate 0–200 s–1 and back again to the start point, each 
stage lasting 120 s).  
Conductivity measurements 
In order to assess both the emulsion type (mode of 
water distribution) and sample stability, conductivity 
measurements were performed in both placebo and 
active cream samples (conductivity meter CDM 230, 
Radiometer, Denmark). All measurements were per-
formed after 7, 30 and 90 days of storage at room 
temperature. 
pH Measurements 
pH measurements were taken by direct immersion 
of pH meter glass electrode (Hanna instruments HI 
9321, USA) in the investigated samples. In order to 
estimate impact of the extract addition to pH value of 
the placebo samples, pH value of the extract per se was 
assessed in its aqueous solution which was prepared by 
putting an excess amount of the extract into 100 mL of 
purified water in Erlenmeyer flasks, which were tightly 
closed and shaken on orbital shaker (KS 260 basic, IKA® 
Werke GmbH & Company KG Germany) at 250 rpm at 
25 °C for 24 h. The samples were then centrifuged 
(Centrifuge MPW-56; MPW Med. Instruments, Poland) 
at 3000 rpm for 30 min to separate the undissolved 
extract. For the assessment of preliminary chemical 
stability, pH value of the tested cream samples was 
measured 7, 30 and 90 days after their preparation. 
In vitro antimicrobial activity  
Antimicrobial activity was performed on Gram-posi-
tive (G+) and Gram-negative (G-) bacterial species– 
–causative agents of skin infections in humans. Aside 
referential strains from American Type of Culture Col-
lection (ATCC), investigated strains isolated from skin 
swabs taken from the diseased persons with skin inf-
ection symptoms were also used (clinical isolates, CI). 
The isolation was made from clinical material delivered 
to the Microbiology Department, Faculty of Veterinary 
Medicine, University of Belgrade, in accordance with 
conventional microbiological methods applied for the 
purpose of isolation and identification [12]. From the 
group of G+ microorganisms, Staphylococcus aureus 
ATCC 25923, Methicillin-resistant Staphylococcus 
aureus (MRSA) ATCC 33591, Staphylococcus epider-
midis (clinical isolate) and Enterococcus faecalis (clinical 
isolate) strains were chosen. From the group of G- bac-
teria, Klebsiella pneumoniae (clinical isolate) and Esche-
richia coli ATCC 25922 strains were selected. 
For the investigation of antimicrobial activity and 
the determination of minimal inhibitory concentrations 
(MICs) of UB extracts (U-SE, U-SOX-E, U-SOX-EtOH and 
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U-MAC), investigated creams (ML-U and P-U) and UA, 
broth microdillution method was applied in accordance 
with the Clinical and Laboratory Standards Institute 
(CLSI) prescriptions for antimicrobial susceptibility 
testing [13,14]. 
Experiments were performed in 96-well microplate 
with "U" bottom (Spektar, Serbia) using cation adjusted 
Mueller Hinton II broth, CAMHB (Becton Dickinson, 
USA) with the addition of 1.6% bromocresol purple 
(Merck, Germany) in final concentration at 0.2 mL/200 
mL for G+ and 1% phenol red (Merck, Germany) at 1 
mL/200 mL for G- bacteria. Bromocresol purple and 
phenol red were added to obtain bacterial growth vis-
ibility. Dimethyl sulfoxide, DMSO (Merck, Germany) 
was used as a solvent for both extracts and creams. For 
the complete dissolving of the creams, DMSO was 
heated in water bath at 60 °C until deposit of creams 
disappeared. Investigated concentrations of both ext-
racts and creams were 2560, 1280, 640, 320, 160, 80, 
40, 20, 10, 5, 2.5, 1.25 and 0.625 μg/mL. The final 
bacterial inoculum density of 5×105 CFU/mL was 
achieved by adding 5 μL of 1–2×107 CFU/mL suspen-
sion of investigated strain in microtiter plate wells with 
100 μL of previously added CAMHB. Microplates were 
incubated for 18–24 h at 37 °C. For MIC values deter-
mination the broth with lowest sample concentration, 
with no visible bacterial growth, was used. 
In vivo skin irritation/performance study 
In vivo skin irritation potential of the investigated 
samples was assessed in a 24-h study under occlusion. 
Thirteen healthy volunteers (mean age 21.92±1.6), 
which participated in the study, were thoroughly 
informed about the possible treatment effects and the 
protocol of the examination prior to signing written 
consents, in accordance with the Helsinki Declaration. 
The study was approved by the Ethical Committee of 
the Faculty of Medicine, University of Niš, Serbia. The 
following parameters were evaluated: erythema index 
(EI), transepidermal water loss (TEWL) and electrical 
capacitance (EC) (quantifying the stratum corneum 
hydration) using Multi Probe Adapter MPA®9 (Courage 
& Khazaka Electronic GmbH, Germany). All measure-
ments were conducted on flexor aspects of forearms at 
square application sites of 9 cm2, leaving a site per each 
arm for untreated control under occlusion (UCO) and 
without occlusion (UC). After initial measurements, 
0.016 g/cm2 of investigative samples were applied, 
covered with silicone film and fixed with hypoallergenic 
adhesive tapes. Two hours upon removal of the 24-h 
occlusion, all parameters were reassessed.  
Statistical analysis 
Statistical analysis was carried out in OriginPro 9.0 
(Electronic Arts, USA). Parameters of in vivo measure-
ments were assessed with a one-way ANOVA followed 
by Tukey post hoc test, whenever appropriate. 
RESULTS AND DISCUSSION 
Results of chemical analysis of UB extracts are pre-
sented in Table 2. UA content ranged from 1.39 % in U- 
-MAC to 81.41% in U-SE, which could be expected, 
bearing in mind that its solubility increases with solvent 
polarity decrease [15]. Namely, the lowest UA content 
was found in the extracts prepared with ethanol, which 
was the most polar solvent used (Table 2). However, 
application of non-polar ether in the extraction process 
led to notable increase in UA content in the sample U-
SOX-E (Table 2). The highest UA content was detected 
in the sample obtained by supercritical CO2 extraction, 
U-SE (Table 2), known to be appropriate method for 
the isolation of low polarity compounds [16].  
All of investigated extracts and pure UA showed 
antimicrobial activity against G+ strains, whereas there 
was no activity against G– bacteria (MICs greater than 
2560 μg/mL), which is in line with previous reports 
[2,4,5]. As expected, MIC values for the G+ bacteria 
were inversely proportional to the UA content, i.e., 
antimicrobial potential increased with the upsurge of 
UA percentage, thus reasserting its mediating role in 
demonstrated antimicrobial activity of UB extracts 
[4,5]. Precisely, among the investigated extracts, 
U-MAC revealed the highest MIC values (representing 
the weakest antimicrobial activity) against investigated 
bacteria, followed by U-SOX-EtOH and U-SOX-E (Table 
2). U-SE was the most effective extract, revealing the 
same MIC values as the pure UA with S. epidermidis 
Table 2. Usnic acid content and minimal inhibitory concentrations (MIC values) of the investigated isolates of U. barbata, expressed 
as μg/mL (usnic acid (UA), supercritical CO2 extract (U-SE), Soxhlet extract-ether fraction (U-SOX-E), Soxhlet extract-ethanol fraction 
(U-SOX-EtOH) and macerate (U-MAC)) 
Extract/isolate Usnic acid content, % 
S. aureus 
ATCC 25923 
MRSA 
ATCC 33591 
S. epidermidis 
(CI) 
E. faecalis 
(CI) 
K. pneumoniae 
(CI) 
E. coli 
ATCC 25922 
UA 98.00 10 5 1.25 2.5 no effect no effect 
U-SE 81.41 10 5 1.25 2.5 no effect no effect 
U-SOX-E 67.09 40 20 5 5 no effect no effect 
U-SOX-EtOH 2.43 320 320 40 160 no effect no effect 
U-MAC 1.39 640 320 160 320 no effect no effect 
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and E. faecalis clinical isolates being the most sensitive 
among the tested bacterial strains (Table 2). 
Thus, U-SE, as the extract with the best antimic-
robial potential, was incorporated into the developed 
APG-based (ML) and pharmacopoeial (P) vehicle in the 
same concentration corresponding to 2 mass% of UA, 
as a carrier of stated biological activity, by suspending 
the extract using mortar and pestle, yielding samples 
ML-U and P-U, respectively. Thereafter, their physico-
chemical stability, efficiency and safety were evaluated 
and compared both mutually and to their corres-
ponding placeboes, in the second part of the study.  
Both placebo samples were shiny, white semisolids, 
with ML having a softer consistency in comparison to P. 
Active samples (ML-U and P-U) were yellowish creams, 
somewhat thicker in comparison to their matching pla-
cebo samples.  
A preliminary physical stability of investigated 
creams was carried out using continual rheology and 
electrical conductivity measurements, while pH value 
measurements gave an insight into their preliminary 
chemical stability. All measurements were carried out 
7, 30 and 90 days after preparation, and tested para-
meters were compared as a function of time.  
Taking into account shear stress–shear rate curves, 
all samples exhibited shear-thinning flow behavior with 
moderate (ML and ML-U) to pronounced (P and P-U) 
thixotropy, considered desirable for topically applied 
preparations (Fig. 1a) [17]. In addition, rheological 
measurements accentuated distinct sensory character-
istics of APG-based samples in comparison to the ref-
erence ones, observed visually. Upon U-SE addition into 
both APG-based and pharmacopoeial vehicle, samples’ 
yield stresses and hysteresis loops were increased, as 
 
Figure 1. Flow curves of: a) all cream samples (alkyl polyglucoside-stabilized vehicle (ML) and pharmacopoeial vehicle (P)) and active 
cream samples with U. barbata supercritical CO2 extract corresponding to 2 mass% of usnic acid in the final formulation incorpor-
ated into vehicle ML (ML-U and P (P-U)) 7 days after preparation, b) sample ML 7 days (ML(7d)) and 90 days (ML(90d)) after prepar-
ation; c) sample ML-U 7 days (ML-U(7d)) and 90 days (ML-U(90d)) after preparation, d) sample P 7 days (P(7d)) and 90 days (P(90d)) 
after preparation, e) sample P-U 7 days (P-U(7d)) and 90 days (P-U (90d)) after preparation.
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expected, considering the fact that the extract was 
suspended in the investigated bases, substantiating 
findings of organoleptic inspection (Fig. 1a). It is a 
known fact that evolution of rheological properties can 
indicate instability of emulsions. Therefore, repeated 
measurements of rheological parameters may serve as 
a simple and convenient experimental method for esti-
mating the state of an emulsion as a function of sto-
rage time [18]. In this accordance, samples ML, ML-U 
and P after 3 months did not show significant changes 
in rheological profiles (Fig. 1 b–d). More specifically, 
the lowest increase of hysteresis loop was recorded in 
APG-based samples, i.e., in ML-U, followed by ML. On 
the other hand, a major upsurge of this rheological 
parameter for P-U, especially in respect to its corres-
ponding placebo (P), could be connected to the dis-
satisfying preliminary physical stability, as well as 
unsatisfactory applicative characteristics of this sample 
(Fig. 1e) [19]. With this respect, continual rheological 
measurements indicated preferential physical stability 
of APG base, especially regarding U-SE incorporation 
potential, when compared to pharmacopoeial one. 
They also emphasized distinctively ameliorated sensory 
characteristics of APG-based samples, as an important 
property of topical preparations having a major impact 
on patients’ compliance and consequent efficacy in the 
management of skin diseases [6]. 
Initial conductivity measurements of the placebo 
samples (ML and P) revealed the values being non-typ-
ical for the multiphase emulsion systems prepared with 
nonionic-mixed emulsifiers (0–50 μs/cm) and in the 
field of real O/W emulsions (Table 3). However, 
although conductivity measurements may indicate the 
degree of structuring and/or the type of emulsion, it is 
not possible to unequivocally interpret high conduct-
ivity solely as reduced structuring of the system, while 
it may also simply reflect the level of free ions present 
within the system [20,21]. Nevertheless, even though 
the only ionic moieties present in both systems origin-
ated from the preservative, potassium sorbate, used in 
the same concentration (Table 1) initially assessed 
specific conductivity detected in APG-based sample 
(ML) was notably higher in comparison to the pharma-
copoeial one (P). This discrepancy might be attributed, 
at least partially, to the higher portion of water within 
the system and therefore probably higher percentage 
of free/bulk water (Table 1) but also the different time 
needed for achieving final microstructure of APG-based 
(ML) versus referent (P) emulsion [21,22]. Later 
assumption was broadly supported by conductivity 
measurements reasserted after 30 days of storage, that 
revealed discernible decrease in specific conductivity of 
APG-based vehicle (ML) pointing to its subsequent 
structuring [20], as opposed to pharmacopoeial one 
(P), having conductivity value at the same level as in 
initial measurements (Table 3). However, further mea-
surement assessed 90 after preparation, disclosed an 
increase of conductivity for both placebo creams (ML 
and P). As for the active samples (ML-U and P-U), 
addition of the extract (U-SE) affected their matching 
vehicles (ML and P, respectively) in an inverse manner 
(Table 3). Namely, in the initial measurements, it led to 
certain decrease of specific conductivity in ML-U rel-
ated to ML that is an increase in P-U connected to P 
(Table 3). In addition, both active creams followed the 
trend of conductivity change as the function of storage 
time pursuant to the corresponding vehicles (Table 3). 
Conductivity increase could point to certain changes 
in physical characteristics of investigated systems and 
might be interpreted as a sign of physical instability, 
and it has been suggested that the later this rise occur-
red and the smaller the growth was, the stability of the 
cream increased [22]. In our experiments, all of the 
investigated cream samples, with the exception of ML, 
revealed an increase of conductivity after 90 days of 
storage at room temperature in comparison to the 
values assessed 7 days after their preparation (Table 3). 
However, when considering an initial decrease of spe-
cific conductivity of APG-based samples (ML and ML-U) 
within first 30 days of room temperature storage, an 
overall growth of conductivity may be considered more 
accentuated in these samples in relation to the refer-
ence ones (P and P-U, Table 3). It is well established 
that for the definitive evaluation of physical stability of 
an emulsion system, parameters assessed using differ-
ent methods are considered relevant. In this regard, 
greater extent of conductivity increase in APG-based 
samples related to the reference ones was not in line 
with previously discussed rheological findings. On the 
other side, P-U was the only sample disclosing perm-
Table 3. Conductivity and pH values of placebo (alkyl polyglucoside-stabilized vehicle (ML) and pharmacopoeial vehicle (P)) and 
active cream samples (with U. barbata supercritical CO2 extract corresponding to 2 mass% of usnic acid in the final formulation 
incorporated into vehicle ML (ML-U) and P (P-U)) assessed 7, 30 and 90 days after preparation 
Sample Conductivity, µS/cm pH 
7 days 30 days 90 days 7 days 30 days 90 days 
ML 204.40 91.50 181.00 7.04 6.95 6.65 
ML-U 199.50 107.30 248.00 6.96 6.98 6.90 
P 73.70 73.30 110.70 7.37 7.15 7.47 
P-U 83.60 85.90 131.60 7.30 7.32 7.47 
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anent increase of conductivity throughout 90-day per-
iod of storage at room temperature. Connected to pre-
viously discussed changes in rheological behavior of 
this sample as a function of the stated storage time, 
such observations should be taken into account in the 
long-term predictions of physical stability of this 
sample. Overall, on the basis of certain dissidences in 
findings of rheological and conductivity measurements, 
additional investigations are needed for the final asses-
sment on physical stability of all investigated cream 
samples. 
pH measurements showed all examined samples to 
be within ranges suitable for skin application (Table 3) 
[6]. Addition of the U-SE in the active samples (ML-U 
and P-U) led to a slight decrease in pH value in com-
parison to corresponding vehicle (ML and P, respect-
ively), which could be expected considering the mea-
sured pH value of the extract per se (5.80). In addition, 
obtained values remained similar throughout the 
3-month observation period, indicating satisfying preli-
minary chemical stability of investigated samples. 
In accordance to the results obtained for the extract 
of UB incorporated into the investigative creams (U- 
-SE), their antimicrobial activity assessment was per-
formed only against G+ bacterial species (the same as 
used for the extracts). Results of antimicrobial activity 
are presented in Table 4. ML and P served as negative 
controls for the appropriate active creams (ML-U and 
P-U, respectively), while ampicillin was used as a posi-
tive control for UA. MICs are presented for UA as a part 
of ML-U and P-U and as intact substance [23]. None of 
the placebo creams (neither ML nor P) showed activity 
against tested microorganisms (MICs greater than 2560 
μg/mL), as seen in Table 4. On the other hand, both 
active creams (ML-U and P-U) revealed the potential to 
inhibit growth of investigated bacteria (Table 4). Accor-
dingly, UA as the active substance of active creams 
followed the same pattern (Table 4). Moreover, 
obtained MIC values were consistent with the ones 
determined for UA per se, revealing strong antimic-
robial activity against tested G+ strains, especially in 
the case of UA as a part of ML-U. With this respect, 
comparison of antimicrobial activity of ML-U versus P-U 
revealed the same inhibition spectrums of both creams 
against MRSA ATCC 33591 and clinical isolate of E. 
faecalis, whereas ML-U was more active against S. 
aureus ATCC 25923 and clinical isolate of S. epidermidis 
(Table 4). In contrast, ampicillin showed no effect 
against most of the tested strains. It was, however, 
more effective than UA against clinical isolate of E. 
faecalis (Table 4).  
Investigated samples showed overall satisfying prel-
iminary safety profiles (Fig. 2). Two hours after occlu-
sion removal, there was no significant change in EI, 
which was even decreased for all investigated samples, 
indicating well-tolerated skin formulations (Fig. 2a). 
TEWL was increased for the samples ML and P-U rel-
ated to corresponding baseline, but not the controls. 
Nevertheless, this increase might be attributed predo-
minantly to the occlusion effect, regarding the fact that 
TEWL obtained for UCO was also significantly higher in 
comparison to the baseline (Fig. 2b). As for EC, all 
samples led to an increase of this parameter (Fig. 2c). 
The increase could be considered significant in the case 
of both APG-based samples (ML and ML-U) compared 
to baselines and both controls, revealing skin hydration 
potential probably related to the vehicle itself, con-
sidering that there was no statistically significant differ-
ences in EC increase between these two samples (Fig. 
2c). The same finding regarding EC was noted for the 
pharmacopoeial vehicle (P), but not the active cream 
(P-U), which EC increase was statistically significant 
compared to UC, but not UCO. 
 
Table 4. Minimal inhibitory concentrations (MIC values), expressed as μg/mL, for the investigated samples: placebo creams (alkyl 
polyglucoside-stabilized vehicle (ML) and pharmacopoeial vehicle (P), negative control); active creams (with U. barbata supercritical 
CO2 extract corresponding to 2 mass% of usnic acid in the final formulation incorporated into vehicle ML (ML-U) and P (P-U)); active 
substance usnic acid (UA, as a part of active cream (ML-U and P-U) and per se) and ampicillin (positive control) 
Sample S. aureus ATCC 25923 MRSA ATCC 33591 S. epidermidis (CI) E. faecalis  (CI) 
ML No effect No effect No effect No effect 
ML-U 1280 320 40 80 
UA (AP ML-U)a 25.6 6.4 0.8 1.6 
P No effect No effect No effect No effect 
P-U 2560 320 80 80 
UA (AP P-U)b 51.2 6.4 1.6 1.6 
UA (per se) 10 5 1.25 2.5 
Ampicillin No effect No effect No effect 0.125 
aMIC of UA as a part of ML-U (AP ML-U) was calculated as the concentration of UA in the cream multiplied by MIC for ML-U; bMIC of UA as a part of 
P-U (AP P-U) was calculated as the concentration of UA in the cream multiplied by MIC for P-U 
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Figure 2. The effects of placebo (alkyl polyglucoside-stabilized vehicle (ML) and pharmacopoeial vehicle (P) and active cream 
samples (cream samples with U. barbata supercritical CO2 extract corresponding to 2 mass% of usnic acid in the final formulation 
incorporated into vehicle ML (ML-U) and P (P-U)) on: a) erythema index (EI), b) transepidermal water loss (TEWL) and c) electrical 
capacitance (EC). The results are shown as absolute changes of mean values and standard error of mean to the baseline. The effects 
of tested formulations were compared mutually and to both controls (under occlusion, UCO and without occlusion, UC). Significant 
differences are marked with* (P < 0.05). 
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CONCLUSION 
Results of our study proved the developed alkyl 
polyglucoside (APG)-based vehicle to be a promising 
carrier for Usnea barbata CO2-supercritical extract (U- 
-SE) in the concentration corresponding to 2 mass% of 
usnic acid, composing a topical formulation with pot-
ential clinical relevance in the treatment of skin infec-
tions. Investigations on rheological behavior of the inv-
estigated cream samples indicated APG-stabilized 
emulsion to possess highly satisfactory ability to remain 
physically stable upon the addition of U-SE, when com-
pared to pharmacopoeial one. However, conductivity 
measurements revealed certain dissidences related to 
rheological findings, imposing the need for additional 
investigations for the final assessment on physical sta-
bility of the investigated emulsion systems. Satisfying 
preliminary chemical stability was shown for all tested 
cream samples. Further efficiency and safety evaluation 
revealed stronger antimicrobial potential of APG-contain-
ing pharmaceutical vehicle when compared to tradition-
ally used pharmacopoeial base of proven quality. Over-
all satisfying preliminary safety profiles were demon-
strated for both APG-based and reference cream samples. 
In all, investigated APG base revealed certain pre-
ferential features as a vehicle for U-SE compared to the 
conventional one, especially considering its improved 
sensory characteristics (confirmed by organoleptic and 
rheological assessment), as a property often decisive 
for the patient compliance. 
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IZVOD 
EMULZIJA STABILIZOVANA ALKIL POLIGLUKOZIDNIM EMULGATOROM KAO POTENCIJALNI NOSAČ ZA 
CO2-NATKRITIČNI EKSTRAKT VRSTE Usnea barbata: PROCENA STABILNOSTI, BEZBEDNOSTI I EFIKASNOSTI 
TOPIKALNE FORMULACIJE 
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(Naučni rad) 
Antimikrobna aktivnost vrste Usnea barbata naročito protiv bakterija koje
učestvuju u patogenezi različitih bolesti kože, dobro je dokumentovana u naučnoj
literaturi. Uprkos tome, ne postoje radovi koji se bave formulacijom topikalnih 
preparata na bazi ovog lišaja namenjenih lečenju kožnih infekcija. U ovoj studiji,
razvijena je podloga stablizovana alkil poliglukozidnim (APG) emulgatorom, kao 
potencijalni nosač za ekstrakt vrste U. barbata koji je pokazao najbolji antimik-
robni potencijal u preliminarnom istraživanju nekoliko ekstrakata dobijenih upo-
trebom različitih ekstragenasa/postupaka. Radi poređenja, odabrani CO2-natkri-
tični ekstrakt je inkorporiran u istoj koncentraciji (koja odgovara 2 mas.%  usnin-
ske kiseline) i istim postupkom izrade u često korišćenu podlogu farmakopejskog 
kvaliteta, a zatim je sprovedeno uporedno istraživanje fizičko-hemijske stabilnosti, 
efikasnosti i bezbednosti na obe grupe uzoraka. Rezulati našeg istraživanja poka-
zali su da se razvijena podloga stabilizovana APG emulgatorom može smatrati
pogodnim nosačem za CO2-natkritični ekstrakt vrste U. barbata, čineći topikalnu 
formulaciju sa potencijalnim kliničkim značajem u terapiji kožnih infekcija. 
Reološka istraživanja pokazala su zadovoljavajuću sposobnost emulzije stabili-
zovane APG emulgatorom da ostane fizički stabilna nakon dodatka CO2-natkri-
tičnog ekstrakta vrste U. barbata, u poređenju sa farmakopejskom. Međutim,
konduktometrijska merenja su pokazala određena neslaganja sa reološkim nala-
zima, namećući potrebu za dodatnim istraživanjima radi konačne procene fizičke
stabilnosti testiranih emulzionih sistema. Izmerene vrednosti pH tokom perioda
od 90 dana čuvanja uzoraka na sobnoj temperaturi ukazale su na zadovoljavajuću 
preliminarnu hemijsku stabilnost svih uzoraka. Dalja istraživanja efikasnosti i bez-
bednosti pokazala su bolji antimikrobni potencijal uzoraka sa podlogom stabili-
zovanom APG emulgatorom u odnosu na tradicionalno upotrebljavanu farma-
kopejsku bazu poznatog kvaliteta. Zadovoljavajući preliminarni bezbedonosni pro-
fili su pokazani kako za uzorke stabilizovane APG emulgatorom tako i za refe-
rentne krem uzorke. Na osnovu navedenog, može se zaključiti da je istraživana 
podloga bazirana na APG emulgatoru pokazala određene povoljnije karakteristike 
kao nosač za CO2-natkritični ekstrakt vrste U. barbata u poređenju sa konven-
cionalno korišćenom podlogom, naročito uzimajući u obzir njene poboljšane sen-
zorne karakteristike, kao osobinu koja je često odlučujuća za komplijansu paci-
jenata. 
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